Efficacy and Safety of a New Immunostimulating Bacterial Lysate in the Prophylaxis of Acute Lower Respiratory Tract Infections: A randomised, open, controlled clinical trial

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 1, 2004, Pages 50-56

  Rossi, Sandro ^a,b   Tazza, Roberto ^a  

^a Pneumology Operative Unit   (Italy)

^b NONE   (Italy)

Author keywords

Bacterial lysate; Immunostimulant; Ismigen , efficacy, safety; Lower respiratory tract infections

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LYSATE; IMMUNOSTIMULATING AGENT; ISMIGEN;

ACUTE DISEASE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOLYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; IMMUNOSTIMULATION; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PATIENT; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; STATISTICAL SIGNIFICANCE; TABLET;

EID: 0742304363     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296936     Document Type: Article

References (27)

1. Powel, R. A., Bust, S. A., Calvertley, P. M. A. et al., Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (GOLD). Am. J. Respir. Crit. Care Med. 163, 1256 (2001)
2. Kilpelainen, M., Terho, E. O., Helenius, H. et al., Farm environment in childhood prevents the development of allergies. Clin. Exp. Allergy 30, 201 (2000)
3. Abbas, A. K., Murphy, K. M., Shaer, A., Functional diversity of Helper T lymphocytes. Nature 383, 787 (1996)
4. Romagnani, S., The role of lymphocytes in allergic disease. J. Allergy Clin. 105, 399 (2000)
5. Siafkas, N. M., Bouros, D., Management of acute exacerbation of COPD. In: D. S. Post, N. M. Siafkas et al. (eds.), Management of COPD (Vl. III), p. 264, Eur. Resp. Mon., Sheffield, UK (1998); Ismigen. Gazzetta Ufficiale n.92 del 20.04.2001
6. O'Donnell, D. E., Assessment of bronchodilators efficacy in symptomatic COPD: is spirometry useful? Chest 117 (Suppl.), 42S (2000)
7. Campbell, H., Acute respiratory infection: a global challenge. Arch. Dis. Child. 73, 281 (1995)
8. Bienestock, J., Befus, O., Gut and bronchus-associated lymphoid tissue. Am. J. Anat. 170, 437 (1984)
9. Bienestock, J., Befus, A. D., Mucosal Immunology bronchial lymphoid tissue. Immunology 41, 249 (1980)
10. Orcel, B., Oral immunization with bacterial extract for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur. Respir. J. 7, 446 (1994)
11. Collet, J. P., Shapiro, S., Ernst, P. et al. and the PARI-IS Study Steering Committee and Research Group. Effect of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156, 1719 (1997)
12. Anthonisen, N. R., OM-85 BV for COPD. Am. J. Respir. Crit. Care Med. 156, 1713 (1997)
13. Murphy, T. F., Sethi, S., State of the Art. Bacterial infections in chronic obstructive pulmonary disease. Ann. Rev. Respir. Dis. 146, 1067 (1992)
14. Sachs, F. L., Chronic Bronchitis. In: J. E. Pennington (ed.), Respiratory Infections: diagnosis and management, pp. 113-124, 2nd ed., Raven Press, New York (1983)
15. Bienestock, J., The derivation, distribution and function of intestinal mucosal lymphocytes. Monogr. Allergy 17, 233 (1981)
16. Mestecky, J., McGhee, J. R., Arnold, R. R. et al., Selective induction of an immune response in human external secretions by ingestion of bacterial antigens. J. Clin. Invest. 61, 731 (1978)
17. Manuel, J., Pham, T. V., Kreis, B. et al., Stimulation by a bacterial extract (Broncho-Vaxom®) of the metabolic and functional activities of murine macrophages. Int. J. Immunopharmacol. 11, 637 (1989)
18. Emmerich, B., Emslander, H. P., Packman, K. et al., Local immunity in patients with chronic bronchitis and the effect of bacterial extract (Broncho-Vaxom®), on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 57, 90 (1990)
19. Lusuardi, M., Capelli, A., Carli, S. et al., Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest 103, 1783 (1993)
20. Duchow, J., Marchant, A., Deville, J. P. et al., Up regulation of adhesion molecules by Broncho-Vaxom® on phagocytic cells. Int. J. Immunopharmacol. 14, 761 (1992)
21. Wood, C. D., Moller, G., Influence of RU41.740, a glycoprotein extract from Klebsiella pneumoniae on the murine immune system. I. T-independent polyclonal B cell activation. J. Immunol. 132, 616 (1984)
22. Rajagopalan, P., Dournon, E., Vilde, J. L. et al., Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract, inhibits the intracellular multiplication of virulent Legionella Pneumophylia sierogroup 1. Infect. Immunol. 55, 2234 (1987)
23. Czerkinski, C., Anjuere, F., Mcghee, J. R. et al., Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170, 197 (1999)
24. Pauwels, R. A., Lofdahl, C. G., Laitinen, L. A. et al., Long-term treatment with inhaled Budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 340, 1948 (1999)
25. Vestbo, J., Sorensen, T., Lange, P. et al., Long-term effect of inhaled Budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353, 1819 (1999)
26. Burge, P. S., Calverley, P. M., Jones, P. W. et al., Randomised, double bind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 320, 1297 (2000)
27. Collet, J. P., Ducruet, T., Haider, S. et al., Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can. Respir. J. 8, 27 (2001)